Pharma-Bio Serv Past Earnings Performance
Past criteria checks 0/6
Pharma-Bio Serv's earnings have been declining at an average annual rate of -27.4%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been declining at an average rate of 7.2% per year.
Key information
-27.4%
Earnings growth rate
-27.4%
EPS growth rate
Life Sciences Industry Growth | 21.5% |
Revenue growth rate | -7.2% |
Return on equity | -6.1% |
Net Margin | -7.8% |
Last Earnings Update | 31 Jul 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Pharma-Bio Serv makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Jul 24 | 11 | -1 | 4 | 0 |
30 Apr 24 | 13 | 0 | 4 | 0 |
31 Jan 24 | 15 | 1 | 4 | 0 |
31 Oct 23 | 17 | 1 | 4 | 0 |
31 Jul 23 | 18 | 2 | 4 | 0 |
30 Apr 23 | 18 | 1 | 4 | 0 |
31 Jan 23 | 19 | 1 | 4 | 0 |
31 Oct 22 | 19 | 1 | 4 | 0 |
31 Jul 22 | 20 | -4 | 9 | 0 |
30 Apr 22 | 21 | -2 | 9 | 0 |
31 Jan 22 | 21 | -2 | 9 | 0 |
31 Oct 21 | 20 | -2 | 9 | 0 |
31 Jul 21 | 20 | 3 | 4 | 0 |
30 Apr 21 | 21 | 1 | 4 | 0 |
31 Jan 21 | 21 | 2 | 4 | 0 |
31 Oct 20 | 22 | 2 | 4 | 0 |
31 Jul 20 | 21 | 2 | 4 | 0 |
30 Apr 20 | 20 | 2 | 5 | 0 |
31 Jan 20 | 20 | 2 | 4 | 0 |
31 Oct 19 | 20 | 2 | 4 | 0 |
31 Jul 19 | 20 | 2 | 5 | 0 |
30 Apr 19 | 20 | 2 | 5 | 0 |
31 Jan 19 | 19 | 2 | 5 | 0 |
31 Oct 18 | 18 | -1 | 5 | 0 |
31 Jul 18 | 13 | -2 | 4 | 0 |
30 Apr 18 | 13 | -3 | 4 | 0 |
31 Jan 18 | 13 | -3 | 4 | 0 |
31 Oct 17 | 13 | -1 | 5 | 0 |
31 Jul 17 | 17 | -1 | 5 | 0 |
30 Apr 17 | 17 | -1 | 6 | 0 |
31 Jan 17 | 19 | -1 | 6 | 0 |
31 Oct 16 | 20 | 0 | 6 | 0 |
31 Jul 16 | 21 | 1 | 6 | 0 |
30 Apr 16 | 22 | 1 | 6 | 0 |
31 Jan 16 | 22 | 2 | 6 | 0 |
31 Oct 15 | 23 | 2 | 6 | 0 |
31 Jul 15 | 25 | 2 | 6 | 0 |
30 Apr 15 | 25 | 2 | 6 | 0 |
31 Jan 15 | 26 | 2 | 6 | 0 |
31 Oct 14 | 28 | 2 | 6 | 0 |
31 Jul 14 | 29 | 3 | 6 | 0 |
30 Apr 14 | 31 | 3 | 6 | 0 |
31 Jan 14 | 32 | 5 | 6 | 0 |
Quality Earnings: PBSV is currently unprofitable.
Growing Profit Margin: PBSV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PBSV is unprofitable, and losses have increased over the past 5 years at a rate of 27.4% per year.
Accelerating Growth: Unable to compare PBSV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PBSV is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-4.7%).
Return on Equity
High ROE: PBSV has a negative Return on Equity (-6.14%), as it is currently unprofitable.